Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
REGENXBIO Inc. reports news on its AAV gene therapy pipeline and manufacturing platform for rare, neuromuscular and retinal diseases. Recurring updates cover RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II; RGX-111 for MPS I; and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy.
Company announcements also include FDA regulatory communications, clinical and preclinical data presentations, financial results, operational highlights, and collaboration activity with partners including Nippon Shinyaku and AbbVie. News on the NAV and NAVXpress platforms addresses AAV vector technology, product quality, and manufacturing capabilities used across REGENXBIO's investigational programs.
REGENXBIO (NASDAQ: RGNX) has secured a strategic royalty monetization agreement with Healthcare Royalty (HCRx) worth up to $250 million. The company received $150 million upfront, extending its cash runway into early 2027. The non-dilutive agreement includes rights to royalties from ZOLGENSMA sales and milestone payments from various partnerships.
Additional funding includes $50 million tied to ZOLGENSMA sales milestones (by April 2027) and another $50 million upon mutual agreement. HCRx will receive quarterly interest payments from royalty revenue and warrants to purchase 268,096 shares at $14.92. REGENXBIO retains rights to other funding sources, including a potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku.
The FDA has accepted and granted Priority Review for REGENXBIO's (NASDAQ: RGNX) Biologics License Application (BLA) for RGX-121, a potential first-in-class gene therapy for Hunter syndrome (MPS II). The FDA has set a PDUFA target action date of November 9, 2025.
RGX-121 has received multiple FDA designations including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and RMAT. Under a partnership announced in January 2025, NS Pharma (Nippon Shinyaku subsidiary) will lead U.S. commercialization post-approval, while REGENXBIO maintains commercial manufacturing and supply chain responsibilities. If approved, REGENXBIO would retain rights to a potential Priority Review Voucher.
The one-time treatment aims to address both neurodevelopmental and systemic effects of Hunter syndrome, potentially replacing current weekly enzyme replacement therapy.- Late-stage clinical trial data for RGX-121 (clemidsogene lanparvovec) for MPS II treatment and RGX-202 for Duchenne muscular dystrophy
The company will deliver three oral presentations focusing on: • Commercial manufacturing process for RGX-202 • RGX-121 gene therapy for neuronopathic mucopolysaccharidosis • RGX-202 interim clinical data for Duchenne muscular dystrophy
Additionally, five poster presentations will cover various aspects of AAV vector development, testing methods, and blood-brain barrier crossing vectors.
REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025. The company will be present at five major healthcare and biotech events:
- BofA Securities Health Care Conference in Las Vegas (May 13)
- RBC Global Healthcare Conference in New York (May 20)
- H.C. Wainwright BioConnect in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
- UBS Spring Biotech Conference in New York (June 24)
Select presentations and fireside chats will be available via webcast on REGENXBIO's website, with recordings accessible for approximately 30 days after each event.
REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Monday, May 12, at 4:30 p.m. ET to present its financial performance for the first quarter ending March 31, 2025, along with recent operational updates.
The company has provided two access options for interested parties:
- General listeners can join via a webcast link
- Analysts can participate in the Q&A session through a separate dedicated link
A recording of the webcast will be made available on REGENXBIO's investor website approximately two hours after the call concludes. Participants are encouraged to connect 15 minutes before the scheduled start time.
REGENXBIO (NASDAQ: RGNX) has reported positive interim data from the AFFINITY DUCHENNE® trial of RGX-202, their investigational gene therapy for Duchenne muscular dystrophy. Key highlights include robust microdystrophin expression levels, with a 3-year-old patient showing 122.3% expression compared to control, and a 7-year-old patient showing 31.5%.
The therapy demonstrates the highest reported vector genome copies (4.9-55.4) measured by qPCR across approved or investigational gene therapies. Safety data as of February 21, 2025, shows RGX-202 was well-tolerated with no serious adverse events. Common side effects included nausea, vomiting, and fatigue, which all resolved.
The Phase III portion of the trial is currently enrolling ambulatory patients aged 1 and above, with BLA submission targeted for mid-2026. Previously reported data from November 2024 showed functional improvements in all five initial participants, exceeding external natural history controls. Additional interim functional data is expected in the first half of 2025.